Scientists Uncover Mechanism Behind Statin Muscle Side Effects, Paving Way for Safer Drugs

Statins have revolutionized cardiovascular health, significantly lowering cholesterol and reducing the risk of heart attacks and strokes. However, these benefits often come with a common drawback: many patients experience muscle pain, weakness, and in rare instances, severe muscle tissue breakdown leading to kidney failure.

Now, researchers from the University of British Columbia and the University of Wisconsin-Madison have identified the precise mechanism triggering these muscle-related issues. Their groundbreaking work, published in Nature Communications, offers a clear path toward developing safer statins free from these challenging complications.

Cryo-EM Reveals Key Mechanism

The scientists utilized cryo-electron microscopy, an advanced imaging technique, to observe how statins interact with ryanodine receptor (RyR1), a vital muscle protein. This protein is critical for muscle contraction, controlling calcium flow within muscle cells, much like a gate.

The study's pivotal finding reveals that when statins bind to RyR1, they force the channel into an open state. This action leads to continuous calcium leakage within the muscle cells.

This leakage can be toxic to muscle tissue, causing damage and explaining observed side effects like muscle pain or severe complications.

Dr. Steven Molinarolo, lead author from UBC, emphasized the significance of this discovery.

"The detailed view of how statins bind to this channel explains the calcium leak and its consequences."

A Multi-Statin Binding Process

While the research specifically examined atorvastatin, a widely prescribed statin, scientists believe this mechanism may extend to other drugs within the statin family. They uncovered a unique binding pattern where three statin molecules cluster within a pocket of the RyR1 protein.

The process begins with an initial statin molecule binding while the channel is closed, preparing it to open. Subsequently, two more statin molecules then force the channel fully open, leading to the sustained calcium leakage.

Designing Safer Statins

This clear understanding offers a significant opportunity for pharmaceutical innovation. Dr. Filip Van Petegem, senior author and professor at UBC's Life Sciences Institute, noted:

"This clear understanding of how statins activate the channel provides a roadmap for designing statins that do not interact with muscle tissue."

By modifying only the specific parts of the statin molecule responsible for these harmful interactions, researchers aim to preserve the essential cholesterol-lowering benefits while effectively mitigating the risk of muscle damage.

Although severe muscle injury affects a small percentage of global statin users, milder symptoms are far more common. These often lead patients to discontinue their medication, undermining critical heart health treatments. These findings could dramatically reduce such side effects and significantly improve patient adherence.

The study powerfully underscores the transformative role of advanced imaging tools in modern medical research. Using UBC's high-resolution macromolecular cryo-electron microscopy facility, the team precisely captured the statin-protein interaction, turning a long-standing safety concern into actionable scientific insight for future, improved therapies.